English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  The highly complex and largely neglected Chagas disease (CD) has become a global health problem due to population movements between Latin America and non-endemic countries, as well as non-vectorial transmission routes. Data on CD testing and treatment from routine patient care in Germany of almost two decades was collected and analysed.    Methods  German laboratories offering diagnostics for chronic  Trypanosoma cruzi  ( T. cruzi ) infection in routine patient care were identified. All retrievable data on tests performed during the years of 2000–2018 were analysed. Additional clinical information regarding patients diagnosed with CD was collected through questionnaires.    Results  Five German laboratories with diagnostics for  T. cruzi  infection in routine patient care were identified. Centres in Hamburg and Munich offered two independent serological tests to confirm the CD diagnosis, as recommended by WHO during the entire time period 2000–2018. Overall, a total of  n  = 10,728 independent tests involving  n  = 5991 individuals were identified with a progressive increase in testing rates over time, only  n  = 130 (16.0%) of the tested individuals with known nationality came from CD endemic countries. Of all test units conducted at the included institutes, a total of  n  = 347/10,728 (3.2%) tests on CD were positive, of which  n  = 200/347 (57.6%) were ELISA,  n  = 133/347 (38.3%) IFT,  n  = 10/347 (2.9%) PCR, and  n  = 4/347 (1.2%) RDT. Of the  n  = 5991 individuals only  n  = 81 (1.4%) with chronic infection were identified,  n  = 52 females and  n  = 28 males. Additional clinical information could only be collected from  n  = 47.    Conclusion  The results of this study give insight into the deployment of screening, detection, diagnosis, and treatment of  T. cruzi  over the last two decades in Germany and existing deficits therein; the creation of guidelines for Germany could be a step forward to improve the existing gaps.    Supplementary Information  The online version contains supplementary material available at 10.1186/s12879-020-05600-8.

bmc infectious diseases

Describing nearly two decades of Chagas disease in Germany and the lessons learned: a retrospective study on screening, detection, diagnosis, and treatment of Trypanosoma cruzi infection from 2000 – 2018